These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38884564)

  • 1. Evaluation of multiple-flows exhaled nitric oxide and its clinical significance in severe asthmatic patients treated with biologics: a prospective real-life study.
    Pianigiani T; Luzzi S; Dilroba A; Meocci M; Salvadori E; Alderighi L; Bergantini L; d'Alessandro M; Sestini P; Bargagli E; Cameli P
    J Asthma; 2024 Jul; ():1-10. PubMed ID: 38884564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma.
    Porsbjerg CM; Townend J; Bergeron C; Christoff GC; Katsoulotos GP; Larenas-Linnemann D; Tran TN; Al-Lehebi R; Bosnic-Anticevich SZ; Busby J; Hew M; Kostikas K; Papadopoulos NG; Pfeffer PE; Popov TA; Rhee CK; Sadatsafavi M; Tsai MJ; Ulrik CS; Al-Ahmad M; Altraja A; Beastall A; Bulathsinhala L; Carter V; Cosio BG; Fletton K; Hansen S; Heaney LG; Hubbard RB; Kuna P; Murray RB; Nagano T; Pini L; Cano Rosales DJ; Schleich F; Wechsler ME; Amaral R; Bourdin A; Brusselle GG; Chen W; Chung LP; Denton E; Fonseca JA; Hoyte F; Jackson DJ; Katial R; Kirenga BJ; Koh MS; Ławkiedraj A; Lehtimäki L; Liew MF; Mahboub B; Martin N; Menzies-Gow AN; Pang PH; Papaioannou AI; Patel PH; Perez-De-Llano L; Peters MJ; Ricciardi L; Rodríguez-Cáceres B; Solarte I; Tay TR; Torres-Duque CA; Wang E; Zappa M; Abisheganaden J; Assing KD; Costello RW; Gibson PG; Heffler E; Máspero J; Nicola S; Perng Steve DW; Puggioni F; Salvi S; Sheu CC; Sirena C; Taillé C; Tan TL; Bjermer L; Canonica GW; Iwanaga T; Jiménez-Maldonado L; Taube C; Brussino L; Price DB
    Front Immunol; 2024; 15():1361891. PubMed ID: 38711495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of FeNO to predict anti-IL-5 and IL-5R biologics efficacy in a real-world cohort of adults with severe eosinophilic asthma.
    Menigoz C; Dirou S; Chambellan A; Hassoun D; Moui A; Magnan A; Blanc FX
    J Asthma; 2023 Jun; 60(6):1162-1170. PubMed ID: 36301080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the Interaction between Fractional Exhaled Nitric Oxide and Biologic Treatment in Severe Asthma: A Systematic Review.
    Pianigiani T; Alderighi L; Meocci M; Messina M; Perea B; Luzzi S; Bergantini L; D'Alessandro M; Refini RM; Bargagli E; Cameli P
    Antioxidants (Basel); 2023 Feb; 12(2):. PubMed ID: 36829959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Resistance in Severe Asthma Patients With a Combination of High Fraction of Exhaled Nitric Oxide and Low Blood Eosinophil Counts.
    Hoshino Y; Soma T; Uchida Y; Shiko Y; Nakagome K; Nagata M
    Front Pharmacol; 2022; 13():836635. PubMed ID: 35517829
    [No Abstract]   [Full Text] [Related]  

  • 6. The Role of Fractional Exhaled Nitric Oxide in Diagnosing Asthmatic Type 2 Chronic Rhinosinusitis With Nasal Polyps.
    Park JA; Cha H; Yang SK; Ryu HT; Kim DW; Hong SN; Yang MS; Kim DW
    Am J Rhinol Allergy; 2023 Sep; 37(5):524-530. PubMed ID: 37160729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increase in FeNO Levels Following IL5/IL5R-Targeting Therapies in Severe Asthma: A Case Series.
    Pelletier G; Godbout K; Boulay MÈ; Boulet LP; Morissette MC; Côté A
    J Asthma Allergy; 2022; 15():691-701. PubMed ID: 35615256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Emerging Role for Exhaled Nitric Oxide in Guiding Biological Treatment in Severe Asthma.
    Rolla G; Heffler E; Pizzimenti S; Michils A; Malinovschi A
    Curr Med Chem; 2020; 27(42):7159-7167. PubMed ID: 32660394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term multicenter comparison shows equivalent efficacy of monoclonal antibodies in severe asthma therapy.
    Kayser MZ; Suhling H; Fuge J; Hinze CA; Drick N; Kneidinger N; Behr J; Taube C; Welte T; Haasler I; Milger K
    BMC Pulm Med; 2024 Mar; 24(1):149. PubMed ID: 38515071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Remission in Patients Affected by Severe Eosinophilic Asthma on Dupilumab Therapy: A Long-Term Real-Life Study.
    Quarato CMI; Tondo P; Lacedonia D; Soccio P; Fuso P; Sabato E; Hoxhallari A; Foschino Barbaro MP; Scioscia G
    J Clin Med; 2024 Jan; 13(1):. PubMed ID: 38202298
    [No Abstract]   [Full Text] [Related]  

  • 11. Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study.
    Detoraki A; Tremante E; D'Amato M; Calabrese C; Casella C; Maniscalco M; Poto R; Brancaccio R; Boccia M; Martino M; Imperatore C; Spadaro G
    Ther Adv Respir Dis; 2021; 15():17534666211009398. PubMed ID: 33910399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of spirometry and exhaled nitric oxide to predict exacerbations in treated asthmatics.
    Gelb AF; Flynn Taylor C; Shinar CM; Gutierrez C; Zamel N
    Chest; 2006 Jun; 129(6):1492-9. PubMed ID: 16778266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic questions the role of eosinophils in mediating the clinical expression of the disease: a case report.
    Sabbe M; Schleich F; Janssens P; Louis R
    J Med Case Rep; 2024 Jan; 18(1):63. PubMed ID: 38291489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early effectiveness of type-2 severe asthma treatment with dupilumab in a real-life setting; a FeNO-driven choice that leads to winning management.
    Carpagnano GE; Scioscia G; Buonamico E; Lacedonia D; Diaferia F; Capozza E; Lepore G; Resta O; Foschino Barbaro MP
    Multidiscip Respir Med; 2022 Jan; 17(1):797. PubMed ID: 35280851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of Clinical Response to Dupilumab in Patients with Severe Asthma Using Fractional Exhaled Nitric Oxide Combined with Pulmonary Function Testing.
    Liu YL; Zhang Y
    Int Arch Allergy Immunol; 2024; 185(9):856-864. PubMed ID: 38688250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dupilumab responder types and predicting factors in patients with type 2 severe asthma: A real-world cohort study.
    Bult L; Thelen JC; Rauh SP; Veen JCCMI'; Braunstahl GJ
    Respir Med; 2024 Sep; 231():107720. PubMed ID: 38992817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Switching Biologics for Severe Asthma Patients in Japan: A Single-Center Retrospective Study.
    Numata T; Araya J; Miyagawa H; Okuda K; Fujita Y; Utsumi H; Takekoshi D; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Kuwano K
    J Asthma Allergy; 2021; 14():609-618. PubMed ID: 34113131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cost comparison of benralizumab, mepolizumab, and dupilumab in patients with severe asthma: A US third-party payer perspective.
    Xu X; Schaefer C; Szende A; Genofre E; Katial R; Chung Y
    J Manag Care Spec Pharm; 2023 Nov; 29(11):1193-1204. PubMed ID: 37796731
    [No Abstract]   [Full Text] [Related]  

  • 19. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.
    McDowell PJ; Diver S; Yang F; Borg C; Busby J; Brown V; Shrimanker R; Cox C; Brightling CE; Chaudhuri R; Pavord ID; Heaney LG;
    Lancet Respir Med; 2021 Oct; 9(10):1174-1184. PubMed ID: 33971168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis.
    Basagaña M; Martínez-Rivera C; Padró C; Garcia-Olivé I; Martínez-Colls M; Navarro J; Pardo L; Cruz P; Cardona Peitx G; Carabias L; Roger A; Abad J; Rosell A
    Ann Med; 2024 Dec; 56(1):2317356. PubMed ID: 38364218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.